Kazia entered into a worldwide exclusive license agreement with Genentech, Inc. (South San Francisco, CA) in October 2016. Under the agreement, Kazia has rights to develop and commercialise GDC-0084, now known as paxalisib.
Oasmia Pharmaceutical AB (Stockholm, Sweden) acquired worldwide exclusive rights to Kazia's Cantrixil (TRX-E-002-1) in March 2021. Oasmia expects to commence a phase II trial of Cantrixil in ovarian cancer in 2022.
In March 2021, Kazia entered into a worldwide exclusive license agreement with Evotec SE (Hamburg, Germany) to develop and commercialise EVT801. Kazia expects to commence a phase I clinical trial in 2021.
Kazia has licensed Greater China rights for paxalisib to Simcere Pharmaceutical Group, one of China's leading pharmaceutical companies. Under the agreement, Simcere will be responsible for certain development activities relating to paxalisib in China, and for commercialisation of the drug in that territory.
